HRP20151369T1 - Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 - Google Patents
Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 Download PDFInfo
- Publication number
- HRP20151369T1 HRP20151369T1 HRP20151369TT HRP20151369T HRP20151369T1 HR P20151369 T1 HRP20151369 T1 HR P20151369T1 HR P20151369T T HRP20151369T T HR P20151369TT HR P20151369 T HRP20151369 T HR P20151369T HR P20151369 T1 HRP20151369 T1 HR P20151369T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical combination
- use according
- subject
- treated
- mmol
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims 3
- 229960003105 metformin Drugs 0.000 title claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 3
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 claims 3
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (13)
1. Farmaceutska kombinacija za uporabu za smanjivanje razine glukagona u plazmi kod pacijenta s dijabetesom tipa 2, naznačena time da navedena kombinacija sadrži
(a) desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegovu farmaceutski prihvatljivu sol,
(b) metformin ili/i njegovu farmaceutski prihvatljivu sol, i
(c) sulfonil ureu,
pri čemu subjekt koji se liječi ima koncentraciju glukoze u plazmi 2 sata nakon obroka od barem 14 mmol/L.
2. Farmaceutska kombinacija za uporabu prema zahtjevu 1, naznačena time da je subjekt koji se liječi pretio.
3. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima indeks tjelesne mase od barem 30 kg/m2.
4. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi je odrasli subjekt.
5. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je kod subjekta koji se liječi, dijabetes melitus tipa 2 dijagnosticiran najmanje 1 godinu ili najmanje 2 godine prije početka terapije.
6. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima vrijednost HbA1C od oko 7 do oko 10%.
7. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima koncentraciju glukoze u plazmi natašte od barem 8 mmol/L.
8. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima promjenu razine glukoze od barem 2 mmol/L, najmanje 3 mmol/L, najmanje 4 mmol/L ili najmanje 5 mmol/L, pri čemu je promjena razine glukoze razlika između koncentracije glukoze u plazmi 2 sata nakon obroka i koncentracije glukoze u plazmi 30 minuta prije testa sa objedom.
9. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je subjekt koji se liječi orijentalne ili/i azijske rase.
10. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol pripremljena za parenteralno davanje.
11. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol pripremljena za davanje u dnevnoj dozi odabranoj u raspona od 10 µg do 20 µg.
12. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je metformin ili/i njegova farmaceutski prihvatljiva sol pripremljena za oralno davanje.
13. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je sulfonil urea pripremljena za oralno davanje.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166120 | 2011-05-13 | ||
| EP12163637 | 2012-04-10 | ||
| EP12723132.2A EP2707017B1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
| PCT/EP2012/058747 WO2012156298A1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151369T1 true HRP20151369T1 (hr) | 2016-01-15 |
Family
ID=46148833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151369TT HRP20151369T1 (hr) | 2011-05-13 | 2015-12-11 | Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130065828A1 (hr) |
| EP (1) | EP2707017B1 (hr) |
| JP (2) | JP6442284B2 (hr) |
| KR (1) | KR20140043755A (hr) |
| CN (2) | CN103841988A (hr) |
| AU (1) | AU2012257849B2 (hr) |
| BR (1) | BR112013029062A2 (hr) |
| CA (1) | CA2835259C (hr) |
| CY (1) | CY1117250T1 (hr) |
| DK (1) | DK2707017T3 (hr) |
| ES (1) | ES2556466T3 (hr) |
| HK (1) | HK1194307A1 (hr) |
| HR (1) | HRP20151369T1 (hr) |
| HU (1) | HUE028459T2 (hr) |
| MX (1) | MX362527B (hr) |
| PL (1) | PL2707017T3 (hr) |
| PT (1) | PT2707017E (hr) |
| RU (1) | RU2623023C2 (hr) |
| SI (1) | SI2707017T1 (hr) |
| WO (1) | WO2012156298A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| PL2498801T3 (pl) | 2009-11-13 | 2018-08-31 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę |
| HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| CN114939156A (zh) | 2014-01-09 | 2022-08-26 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
| KR20160104724A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형 |
| SG11201604708VA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| US20160235818A1 (en) * | 2015-01-16 | 2016-08-18 | Sanofi-Aventis Deutschland Gmbh | Treatment of Pediatric Type 2 Diabetes Mellitus Patients |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| EP2248531A1 (en) * | 2004-08-03 | 2010-11-10 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| CN101291685A (zh) * | 2005-08-19 | 2008-10-22 | 安米林药品公司 | 治疗糖尿病和降低体重的毒蜥外泌肽 |
| JP5399244B2 (ja) * | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド |
| EP2395988A2 (en) * | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| ES2553593T3 (es) | 2009-11-13 | 2015-12-10 | Sanofi-Aventis Deutschland Gmbh | Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
-
2012
- 2012-05-11 AU AU2012257849A patent/AU2012257849B2/en active Active
- 2012-05-11 US US13/469,633 patent/US20130065828A1/en not_active Abandoned
- 2012-05-11 WO PCT/EP2012/058747 patent/WO2012156298A1/en active Application Filing
- 2012-05-11 EP EP12723132.2A patent/EP2707017B1/en not_active Revoked
- 2012-05-11 RU RU2013155474A patent/RU2623023C2/ru active
- 2012-05-11 DK DK12723132.2T patent/DK2707017T3/en active
- 2012-05-11 KR KR1020137033310A patent/KR20140043755A/ko active Search and Examination
- 2012-05-11 CA CA2835259A patent/CA2835259C/en active Active
- 2012-05-11 BR BR112013029062A patent/BR112013029062A2/pt not_active Application Discontinuation
- 2012-05-11 JP JP2014509752A patent/JP6442284B2/ja active Active
- 2012-05-11 CN CN201280034737.4A patent/CN103841988A/zh active Pending
- 2012-05-11 MX MX2013013307A patent/MX362527B/es active IP Right Grant
- 2012-05-11 HU HUE12723132A patent/HUE028459T2/en unknown
- 2012-05-11 PL PL12723132T patent/PL2707017T3/pl unknown
- 2012-05-11 ES ES12723132.2T patent/ES2556466T3/es active Active
- 2012-05-11 CN CN201711058028.0A patent/CN107693782A/zh active Pending
- 2012-05-11 PT PT127231322T patent/PT2707017E/pt unknown
- 2012-05-11 SI SI201230377T patent/SI2707017T1/sl unknown
-
2014
- 2014-08-04 HK HK14107943.7A patent/HK1194307A1/xx not_active IP Right Cessation
-
2015
- 2015-12-11 HR HRP20151369TT patent/HRP20151369T1/hr unknown
- 2015-12-15 CY CY20151101144T patent/CY1117250T1/el unknown
-
2018
- 2018-07-20 JP JP2018136356A patent/JP6676108B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140043755A (ko) | 2014-04-10 |
| JP2018184441A (ja) | 2018-11-22 |
| JP6442284B2 (ja) | 2018-12-19 |
| HK1194307A1 (en) | 2014-10-17 |
| US20130065828A1 (en) | 2013-03-14 |
| CN107693782A (zh) | 2018-02-16 |
| HUE028459T2 (en) | 2016-12-28 |
| MX2013013307A (es) | 2014-03-12 |
| CN103841988A (zh) | 2014-06-04 |
| MX362527B (es) | 2019-01-23 |
| CA2835259A1 (en) | 2012-11-22 |
| ES2556466T3 (es) | 2016-01-18 |
| RU2623023C2 (ru) | 2017-06-21 |
| CY1117250T1 (el) | 2017-04-05 |
| WO2012156298A1 (en) | 2012-11-22 |
| BR112013029062A2 (pt) | 2016-11-29 |
| DK2707017T3 (en) | 2016-01-04 |
| RU2013155474A (ru) | 2015-06-20 |
| SI2707017T1 (sl) | 2016-01-29 |
| CA2835259C (en) | 2020-01-07 |
| AU2012257849B2 (en) | 2017-03-30 |
| JP2014514356A (ja) | 2014-06-19 |
| EP2707017A1 (en) | 2014-03-19 |
| EP2707017B1 (en) | 2015-09-16 |
| PT2707017E (pt) | 2016-01-12 |
| JP6676108B2 (ja) | 2020-04-08 |
| PL2707017T3 (pl) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151369T1 (hr) | Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 | |
| HRP20151068T1 (hr) | Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2 | |
| HRP20161620T1 (hr) | Uporaba ave0010 za proizvodnju lijeka za liječenje dijabetes melitusa tip 2 | |
| HRP20121029T4 (hr) | Liksisenatid kao pomoćna terapija uz inzulin glargin i metformin kod liječenja dijabetesa tip 2 | |
| Sokar et al. | Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats | |
| WO2013173417A3 (en) | Glucokinase activator compositions for the treatment of diabetes | |
| RU2013155473A (ru) | Фармацевтическая комбинация для применения для индуцирования потери массы тела у субъектов с диабетом 2 типа или/и для предотвращения набора массы тела у субъектов с диабетом 2 типа | |
| RU2017129878A (ru) | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа | |
| Paolisso et al. | Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? | |
| AR078517A1 (es) | Composicion farmaceutica, forma de dosificacion farmaceutica, procedimiento para su preparacion, metodos para su tratamiento y sus usos | |
| HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
| HRP20151087T1 (hr) | Prevencija hipoglikemije kod pacijenata s dijabetesom tipa 2 | |
| BR112015007685A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/glucagon | |
| HRP20131120T1 (hr) | Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa | |
| JP2011241213A5 (hr) | ||
| BRPI1007945A2 (pt) | Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente | |
| Rizzo et al. | Incretin-based therapies, glucometabolic health and endovascular inflammation | |
| Ma et al. | heme oxygenase-1 agonist CoPP suppresses influenza virus replication through IRF3-mediated generation of IFN-α/β | |
| JP2018503644A5 (hr) | ||
| Wu et al. | Effects of metformin on endothelial function in type 2 diabetes | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| EA201792030A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| Mu et al. | Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naive Asian patients with type 2 diabetes | |
| BR112013030171A2 (pt) | composição comestível, método para reduzir a amplitude de pico de glicose pós-prandial no sangue ou resposta glicêmica em uma pessoa não diabética, método para tratar uma pessoa com necessidade de tratamento para diabetes do tipo 2 e uso da composição | |
| Iantorno et al. | Gut hormones and endothelial dysfunction in patients with obesity and diabetes |